ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Status: Recruiting
Location: See all (40) locations...
Study Type: Observational
SUMMARY
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
• Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
Locations
United States
California
Clinical Trial Site
RECRUITING
La Jolla
Clinical Trial Site
RECRUITING
Los Angeles
Florida
Clinical Trial Site
RECRUITING
Jacksonville
Iowa
Clinical Trial Site
RECRUITING
Iowa City
Kansas
Clinical Trial Site
RECRUITING
Kansas City
Massachusetts
Clinical Trial Site
COMPLETED
Boston
Maryland
Clinical Trial Site
RECRUITING
Baltimore
North Carolina
Clinical Trial Site
RECRUITING
Durham
New York
Clinical Trial Site
RECRUITING
New York
Ohio
Clinical Trial Site
RECRUITING
Columbus
Pennsylvania
Clinical Trial Site
RECRUITING
Philadelphia
Texas
Clinical Trial Site
RECRUITING
Austin
Clinical Trial Site
RECRUITING
Houston
Other Locations
Brazil
Clinical Trial Site
RECRUITING
Salvador
Clinical Trial Site
RECRUITING
São Paulo
Bulgaria
Clinical Trial Site
RECRUITING
Sofia
Denmark
Clinical Trial Site
RECRUITING
Aarhus
Clinical Trial Site
RECRUITING
Copenhagen
France
Clinical Trial Site
RECRUITING
Bordeaux
Clinical Trial Site
RECRUITING
Bron
Clinical Trial Site
RECRUITING
Créteil
Clinical Trial Site
RECRUITING
Le Kremlin-bicêtre
Clinical Trial Site
RECRUITING
Marseille
Germany
Clinical Trial Site
RECRUITING
Berlin
Clinical Trial Site
RECRUITING
Giessen
Clinical Trial Site
RECRUITING
Hanover
Israel
Clinical Trial Site
RECRUITING
Jerusalem
Clinical Trial Site
RECRUITING
Ramat Gan
Italy
Clinical Trial Site
RECRUITING
Milan
Clinical Trial Site
RECRUITING
Naples
Clinical Trial Site
RECRUITING
Palermo
Clinical Trial Site
RECRUITING
Roma
Netherlands
Clinical Trial Site
RECRUITING
Groningen
Portugal
Clinical Trial Site
RECRUITING
Lisbon
Clinical Trial Site
RECRUITING
Porto
Spain
Clinical Trial Site
RECRUITING
Barcelona
Clinical Trial Site
RECRUITING
Madrid
Clinical Trial Site
RECRUITING
Palma
Taiwan
Clinical Trial Site
RECRUITING
New Taipei City
Clinical Trial Site
RECRUITING
Taipei
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2020-11-23
Estimated Completion Date: 2030-09-01
Participants
Target number of participants: 1500
Treatments
Patients with ATTR amyloidosis
Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
Pre-symptomatic Carriers
Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals